Loading
HDP-102 is an experimental antibody-drug conjugate with an amanitin payload from Heidelberg Pharma, in phase 1 trials for non-Hodgkin lymphoma; development is paused.
HDP-102 (CD37-ATAC) is an antibody-drug conjugate with an amanitin payload (ATAC) from Heidelberg Pharma. An amanitin conjugate targeting CD37, which is overexpressed on B-cell lymphoma cells. Its furthest stage is phase 1, for non-Hodgkin lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. First patient dosed end of May 2025; recruitment paused after the first cohort after the September 2025 strategic review, all trial centres closed; partner sought (company page). It has not been shown to work in people.
An amanitin conjugate targeting CD37, which is overexpressed on B-cell lymphoma cells.
1.HDP-102's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HDP-102" OR ABSTRACT:"HDP-102" OR TITLE:"CD37-ATAC" OR ABSTRACT:"CD37-ATAC") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HDP-102, not a curated reading list.
Shares Heidelberg Pharma and the tag pipeline.
Shares Heidelberg Pharma and the tag pipeline.
Shares Heidelberg Pharma and the tag pipeline.
Shares Heidelberg Pharma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/